title: Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells.
authors: Irina
authors: I
authors: Idler
authors: Krzysztof
authors: K
authors: Giannopoulos
authors: Thorsten
authors: T
authors: Zenz
authors: Nupur
authors: N
authors: Bhattacharya
authors: Maria
authors: M
authors: Nothing
authors: Hartmut
authors: H
authors: Döhner
authors: Stephan
authors: S
authors: Stilgenbauer
authors: Daniel
authors: D
authors: Mertens
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D020381:Interleukin-17 / Q000032:analysis; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D020381:Interleukin-17; D013792:Thalidomide; D000077269:Lenalidomide